癌症和外周动脉疾病（PAD）具有重叠的危险因素和常见的遗传易感性。关于PAD和癌症对患者的并发影响尚未得到很好的研究。本回顾性研究的目的是评估患有PAD的癌症患者的预后。查询了Memorial Sloan Kettering Cancer Center的数据库以评估既有PAD诊断（使用ICD 9和10代码），又没有PAD诊断的患者的预后。纳入标准为在2013年1月1日至2018年12月12日期间被诊断为肺癌、结直肠癌、前列腺癌、膀胱癌或乳腺癌的患者。共纳入了77,014名患者。其中1,426名患者（1.8%，95% CI 1.8-1.9）被诊断为PAD。PAD诊断在膀胱癌患者（4.7%，95% CI 4.1-5.2）和肺癌患者（4.6%，95% CI 4.2-4.9）中最为常见。在根据癌症诊断、癌症诊断年龄、分期、糖尿病、高血脂、高血压、冠心病、脑血管疾病、吸烟史和BMI> 30进行调整的回归模型中，PAD患者UCW住院率的几率较高（OR 1.50，95%CI 1.32-1.70，P <0.001），住院率的几率较高（OR 1.32，95%CI 1.16-1.50，P <0.001），以及ICU住院率的几率较高（OR 1.64，95%CI 1.31-2.03，P <0.001）。在根据这些相同因素进行调整的情况下，相对于没有PAD的患者，PAD患者死亡风险高出13%（HR 1.13，95% CI 1.04-1.22，P = 0.003）。即使在调整冠心病、中风、其他合并症、癌症诊断和癌症分期的情况下，相对于没有PAD的癌症患者，患有PAD的癌症患者与ICU住院率、UCW就诊率、住院率和死亡率较高。版权所有 © 2023 Elsevier Inc. 保留所有权利。

Cancer and peripheral arterial disease (PAD) have overlapping risk factors and common genetic predispositions. The concomitant effects of PAD and cancer on patients have not been well studied. The objective of this retrospective study is to evaluate outcomes of cancer patients with PAD. A query was made into Memorial Sloan Kettering Cancer Center's database to assess outcome of patients with and without the diagnosis of PAD (using ICD 9 and 10 codes). Inclusion criteria were patients diagnosed with lung, colon, prostate, bladder, or breast cancer between January 1, 2013 and December 12, 2018. A total of 77,014 patients were included in this cohort. 1,426 patients (1.8%, 95% CI 1.8-1.9) carried a diagnosis of PAD. PAD diagnosis was most prevalent in bladder cancer (4.7%, 95% CI 4.1-5.2) and lung cancer patients (4.6%, 95% CI 4.2-4.9). In regression models adjusted for cancer diagnosis, age at cancer diagnosis, stage, diabetes, hyperlipidemia, hypertension, coronary artery disease, cerebrovascular disease, smoking, and BMI > 30, patients with PAD had significantly higher odds of UCC admissions (OR 1.50, 95%CI 1.32-1.70, P < 0.001), inpatient admissions (OR 1.32, 95%CI 1.16-1.50, P < 0.001), and ICU admissions (OR 1.64, 95%CI 1.31-2.03, P < 0.001). After adjusting for all these same factors, patients with PAD had a 13% higher risk of dying relative to patients without PAD (HR 1.13, 95% CI 1.04-1.22, P = 0.003). Cancer patients with PAD had higher risks of ICU stays, UCC visits, inpatient admissions, and mortality compared to cancer patients without PAD even when adjusting for CAD, stroke, other comorbidities, cancer diagnosis, and cancer stage.Copyright © 2023 Elsevier Inc. All rights reserved.